The global Oncology Based In vivo CRO Marketstudy analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Indication (Blood Cancer, Solid Tumors, Others), By Model (Syngeneic, Xenograft, Patient Derived Xenograft).
Supporting preclinical oncology research and drug development, the Oncology-Based In Vivo CRO (Contract Research Organization) market offers specialized contract services for conducting in vivo studies using animal models of cancer to evaluate the safety, efficacy, and pharmacokinetics of oncology therapeutics. In vivo CRO services include tumor xenograft models, patient-derived xenograft (PDX) models, syngeneic models, and genetically engineered mouse models (GEMMs), providing comprehensive preclinical assessment services from compound screening to regulatory submission support. The market's growth is driven by the increasing complexity of oncology drug development, demand for translational research models, and outsourcing trends in the pharmaceutical and biotechnology industries accelerating preclinical oncology studies.
A significant trend in the Oncology Based In vivo CRO market is the increasing demand for oncology drug development services. With the rising prevalence of cancer and the growing pipeline of oncology therapeutics, there is a heightened demand for preclinical and translational research services to support the development of novel cancer therapies. This trend reflects the pharmaceutical and biotechnology industries' focus on oncology as a key therapeutic area, driving the need for specialized contract research organizations (CROs) offering in vivo preclinical models, efficacy studies, pharmacokinetic assessments, and other oncology-focused services to accelerate drug discovery and development programs.
The primary driver propelling the Oncology Based In vivo CRO market is the growth in cancer incidence and healthcare expenditure. With cancer continuing to be a leading cause of morbidity and mortality worldwide, there is significant investment in cancer research, drug discovery, and clinical development efforts to address the unmet medical needs of patients with cancer. As healthcare systems allocate substantial resources towards oncology research and development, pharmaceutical companies, biotech firms, and academic institutions increasingly rely on in vivo CROs to conduct preclinical studies, validate therapeutic targets, and assess the efficacy and safety of investigational oncology drugs. The growing healthcare expenditure on cancer-related research and development initiatives is fueling the demand for oncology-based in vivo CRO services, driving market growth and innovation in preclinical oncology research.
An exciting opportunity in the Oncology Based In vivo CRO market lies in the expansion into immuno-oncology and precision medicine services. With the emergence of immuno-oncology therapies, targeted anticancer agents, and biomarker-driven treatment approaches, there is a growing demand for specialized preclinical models, translational research platforms, and predictive biomarker assays to support the development of immunotherapies and precision oncology drugs. Contract research organizations (CROs) specializing in in vivo oncology studies can capitalize on this opportunity by offering tailored services for immuno-oncology efficacy studies, combination therapy evaluations, patient-derived xenograft (PDX) models, and companion diagnostic development. By expanding into immuno-oncology and precision medicine services, oncology-based in vivo CROs can diversify their service portfolios, differentiate themselves in the competitive market, and address the evolving needs of biopharmaceutical clients seeking innovative solutions for advancing oncology drug development programs.
By Indication
Blood Cancer
Solid Tumors
Others
By Model
Syngeneic
Xenograft
Patient Derived Xenograft (PDX)
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Charles River Laboratory
Crown Bioscience
Eurofins Scientific
EVOTEC
ICON Plc
LabCorp
Taconic Biosciences
The Jackson Laboratory
Thermo Fisher Scientific Inc
WuXi AppTec
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Oncology Based In vivo CRO Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Oncology Based In vivo CRO Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Oncology Based In vivo CRO Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Oncology Based In vivo CRO Market Size Outlook, $ Million, 2021 to 2030
3.2 Oncology Based In vivo CRO Market Outlook by Type, $ Million, 2021 to 2030
3.3 Oncology Based In vivo CRO Market Outlook by Product, $ Million, 2021 to 2030
3.4 Oncology Based In vivo CRO Market Outlook by Application, $ Million, 2021 to 2030
3.5 Oncology Based In vivo CRO Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Oncology Based In vivo CRO Industry
4.2 Key Market Trends in Oncology Based In vivo CRO Industry
4.3 Potential Opportunities in Oncology Based In vivo CRO Industry
4.4 Key Challenges in Oncology Based In vivo CRO Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Oncology Based In vivo CRO Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Oncology Based In vivo CRO Market Outlook by Segments
7.1 Oncology Based In vivo CRO Market Outlook by Segments, $ Million, 2021- 2030
By Indication
Blood Cancer
Solid Tumors
Others
By Model
Syngeneic
Xenograft
Patient Derived Xenograft (PDX)
8 North America Oncology Based In vivo CRO Market Analysis and Outlook To 2030
8.1 Introduction to North America Oncology Based In vivo CRO Markets in 2024
8.2 North America Oncology Based In vivo CRO Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Oncology Based In vivo CRO Market size Outlook by Segments, 2021-2030
By Indication
Blood Cancer
Solid Tumors
Others
By Model
Syngeneic
Xenograft
Patient Derived Xenograft (PDX)
9 Europe Oncology Based In vivo CRO Market Analysis and Outlook To 2030
9.1 Introduction to Europe Oncology Based In vivo CRO Markets in 2024
9.2 Europe Oncology Based In vivo CRO Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Oncology Based In vivo CRO Market Size Outlook by Segments, 2021-2030
By Indication
Blood Cancer
Solid Tumors
Others
By Model
Syngeneic
Xenograft
Patient Derived Xenograft (PDX)
10 Asia Pacific Oncology Based In vivo CRO Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Oncology Based In vivo CRO Markets in 2024
10.2 Asia Pacific Oncology Based In vivo CRO Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Oncology Based In vivo CRO Market size Outlook by Segments, 2021-2030
By Indication
Blood Cancer
Solid Tumors
Others
By Model
Syngeneic
Xenograft
Patient Derived Xenograft (PDX)
11 South America Oncology Based In vivo CRO Market Analysis and Outlook To 2030
11.1 Introduction to South America Oncology Based In vivo CRO Markets in 2024
11.2 South America Oncology Based In vivo CRO Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Oncology Based In vivo CRO Market size Outlook by Segments, 2021-2030
By Indication
Blood Cancer
Solid Tumors
Others
By Model
Syngeneic
Xenograft
Patient Derived Xenograft (PDX)
12 Middle East and Africa Oncology Based In vivo CRO Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Oncology Based In vivo CRO Markets in 2024
12.2 Middle East and Africa Oncology Based In vivo CRO Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Oncology Based In vivo CRO Market size Outlook by Segments, 2021-2030
By Indication
Blood Cancer
Solid Tumors
Others
By Model
Syngeneic
Xenograft
Patient Derived Xenograft (PDX)
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Charles River Laboratory
Crown Bioscience
Eurofins Scientific
EVOTEC
ICON Plc
LabCorp
Taconic Biosciences
The Jackson Laboratory
Thermo Fisher Scientific Inc
WuXi AppTec
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Indication
Blood Cancer
Solid Tumors
Others
By Model
Syngeneic
Xenograft
Patient Derived Xenograft (PDX)
The global Oncology Based In vivo CRO Market is one of the lucrative growth markets, poised to register a 8.6% growth (CAGR) between 2024 and 2030.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Charles River Laboratory, Crown Bioscience, Eurofins Scientific, EVOTEC, ICON Plc, LabCorp, Taconic Biosciences, The Jackson Laboratory, Thermo Fisher Scientific Inc, WuXi AppTec
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume